Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Lifts full-year outlook as obesity drug boom accelerates
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
After Phase 3 results show major hair regrowth gains
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The submission is backed by positive results from the Phase 3 AFFIRM study
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
Subscribe To Our Newsletter & Stay Updated
